港股異動丨京東健康(6618.HK)漲超9% 獲多家機構唱好
格隆匯1月11日丨京東健康(6618.HK)午後升超9%,現報153.1港元,暫成交9.42億港元,總市值4875億港元。近日公司持續獲多家投行集體唱好。瑞銀指出,京東健康為內地醫療健康行業潛在龍頭,風險及回報取得平衡,首予“中性”評級,目標價150港元。美銀證券首予京東健康“買入”評級,目標價看高至166港元。美銀預期其2019-22年收益年增長複合率達52%,達到379億元人民幣,且預計其核心在線零售藥房業務的份額正在提升。華創證券曾表示,考慮到京東健康自營業務佔比較高,給予一定估值溢價。預計2021年集團GMV 約為1053.91億港元,故給予目標價為188.79港元,給予“強推”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.